HeartBeam Inc. (NASDAQ: BEAT) is advancing cardiac care with its FDA-cleared HeartBeam System, the first cable-free electrocardiogram (ECG) device that captures the heart’s electrical signals from three distinct directions. This innovation addresses a growing need for accurate at-home ECG monitoring, particularly for detecting arrhythmias that standard devices may miss.
The HeartBeam System’s patented approach records signals from multiple angles, providing a more comprehensive view of cardiac electrical activity compared to traditional single-perspective devices. This expanded data capture is designed to improve diagnostic precision, especially for intermittent arrhythmias that occur sporadically. Patients can keep the portable device with them at all times and record an ECG at the onset of symptoms, potentially reducing delays in diagnosis and treatment.
“HeartBeam’s proprietary system allows for high-fidelity measurements without the complexity of conventional equipment,” notes the company. Unlike standard devices that capture electrical signals from limited perspectives, HeartBeam’s technology records from three distinct angles, enabling a more complete view of the heart’s electrical activity. This is intended to improve diagnostic precision, particularly for arrhythmias that may be missed with traditional methods.
The platform technology underlying the HeartBeam System is designed to be used in portable devices that can be deployed wherever the patient is, delivering actionable heart intelligence to physicians. This capability allows for the identification of cardiac health trends and acute conditions outside of a medical facility, redefining the future of cardiac health management.
HeartBeam holds 13 U.S. and 4 international-issued patents related to its technology. For more information, visit www.HeartBeam.com. The latest news and updates about BEAT are available in the company’s newsroom at https://ibn.fm/BEAT.
